Search PubMed⌕ Search

Biomedical subjects

A Ariyoshi

Publications and source records attributed to A Ariyoshi.

44 records · Page 3Linked to original sources
PubMed1981

Diagnostic procedures for assessment of disease extent in prostatic carcinoma.

Staging of carcinoma of the prostate was performed on patients using Watanabe's method of transrectal ultrasonotomography (N = 37), pedal lymphography (N = 10), and bone scanning with technetium phosphate (N = 35). Of 14 patients found to have tumor confined within the prostate following routine examination, 4 were elevated to a higher disease stage after sonographic evaluation. Thirty-two percent of 25 patients with normal bone X-rays had abnormal bone scans. Four cases with positive node metastases on lymphogram had already presented with skeletal involvement. The values of these techniques in the assessment of disease extent in prostatic carcinoma are compared and briefly discussed.

Bone Neoplasms↗
PubMed1975

Catheterless cutaneous ureterostomy.

New procedures for tubeless cutaneous ureterostomy are described. The fundamental principles of the methods are 1) an everted ureteral nipple formation combined with a triangular skin flap as a permanent stoma and 2) a 2-stage operation to obtain a viable ureteral nipple against slough and retraction.

Humans↗
PubMedDate not supplied

Carcinoma-associated antigens MK-1 and CEA in urological cancers.

BACKGROUND: The MK-1 antigen, recognized by monoclonal antibody FU-MK-1, is widely associated with human carcinomas. However, the expression and distribution of MK-1 in urological cancers is not well known. MATERIALS AND METHODS: We examined the expression of MK-1 in 10 urological tumor cell lines using flow cytometry and reverse transcription-polymerase chain reaction (RT-PCR) and in 15 cancer tissue specimens by immunohistochemical staining, and then compared it with that of carcinoembryonic antigen (CEA). RESULTS: When analyzed by flow cytometry, MK-1 was positive in 2 out of 3 bladder, 3 out of 3 prostate and one out of 4 renal tumor cell lines, whereas CEA was negative in all the 10 tumor cell lines. RT-PCR confirmed the presence of MK-1 mRNA in all the six MK-1-positive tumor cell lines. An immunohistochemical study demonstrated that MK-1 was positive in 2 out of 5 bladder, 2 out of 5 prostate and one out of 5 renal cancer tissues. Again, however, CEA was negative in all the 15 urological cancer tissues tested. CONCLUSION: These findings suggest that MK-1 seems to be a useful biological marker for malignant urological tumors, especially in cases of bladder and prostate cancer.

Antibodies, Monoclonal↗